Process and intermediates for resolving piperidyl acetamide...

Details Process and intermediates for resolving piperidyl acetamide... Process and intermediates for resolving piperidyl acetamide...

2005-11-08

2005-11-08

Chang, Ceila (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

06962997

ABSTRACT:
Processes and intermediates for preparing 2-substituted piperidines such as 2-substituted d-threo piperidines are provided, including processes and intermediates for resolution of piperidyl acetamide stereoisomers.

REFERENCES:
patent: 2507631 (1950-05-01), Hartmann et al.
patent: 2957880 (1960-10-01), Rometsch
patent: 4410700 (1983-10-01), Rice
patent: 5936091 (1999-08-01), Khetani et al.
Jursic et al. “determination of enantiomeric composition of 1-phenyl . . . ” Tetrahedron:assymetry, v/5 1711-1716 (1994).
Patrick et al. “Synthesis of deuterium . . . ” J. Label. Pharm. v.9, 485-490 (1982).
Berrang et al. “Enantiomeric aminopropiophenones” Ca 97:38738 (1982).
Ohashie et al. “Acylaminonaphthaniene . . . ” CA 104:186157 (1985).
Banderplas et al. “A convenient synthesis of . . . ” CA 118:101538 (1992).
Jursic et al. “Determination of enantiomeric composition of 1-phenyl-2(2-piperidinyl-acetamide” Tetrahedron:asymmetry v/5, 1711-1716 (1994).
Patrick et al. “Synthesis of deuterium labelled methylphenidate . . . ” J. Label. Pharm. v.9, p. 485-490 (1982).
Berrang et al. “Enantiomeric aminopropiophenones” CA 97:38738 (1982).
Ohashie et al. “Acylaminonaphthanlene derivatives” CA 104:186157 (1985).
Feng et al. “molecular determinants of the platelet . . . ” CA 117:111440, 1992.
Morrison and Byd “Orgainc Chemistry” Allyn and Bacon, 1973, p. 32-34.
CAS RN 6051-31-6 or RN 3019-58-7.
Vanderplas et al. “A convenient synthesis of cis-benayl-hydroxymethyl cyclohexylamine” CA 118:101538 (1992).
Dobashi et al. “Entioselectivity of hydrogen bond . . . ” CA 106:66522, 1986.
Japan Chem Soc. “Organic Reaction” v. 1, No. 18, p. 504-505 (translation attached), 1958.
Brown, G., “The use of methylphenidate for cognitive decline associated with HIV disease,”Int'l J. Psychiatry Med., 1995, 25(1), 21-37.
Greenhill, L., “Attention-deficit hyperactivity disorder,”Child & Adol. Psych. Clin. N.A., 1995, 4(1), 123-168.
Phashi, et al., “Acyl(amino)naphthanlene derivatives,”CA104:186157, 1985.
Aoyama, T., et al., “Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers,”Eur. J. Clin. Pharmacol., 1993, 44, 79-84.
Barkley, R. A., et al., “The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study,”J. Am. Acad. Adolesc. Psychiatry., 1990, 29(4), 546-557.
Bruera, E., and Neumann, C.M., “The uses of phychotropics in symptom management in advanced cancer,”Phycho-Oncology., 1998, 7, 346-358.
Garland, E. J., “Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats,”J. Physchopharmacology., 1998, 12(4), 385-395.
Golden, G. S., “Role of attention deficit hyperactivity disorder in learning disabilities,”Seminars in Neurology., 1991, 11(1), 35-41.
Goldman, L. S., et al., “Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents,”J. Am. Med. Assn., 1998, 279(14), 1100-1107.
No author, “Methylphenidate hydrochloride,” Environmental Health Perspectives, 1997, 105 (supp 1), 319.
Patrick, K. S., et al., “Pharmacology of the enantiomers of threo-methylphenidate,”J. Pharmacol. Expt. Ther., 1987, 241, 152-158.
Spencer, T., et al., “Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle,”J. Am. Acad. Adolesc. Psychiatry., 1996, 35(4), 409-432.
Shrinvas, N. R., et al., “Enantioselective pharmacokinetics and pharmacodynamics ofd,l-threo-methylphenidate in children with attention deficit hyperactivity disorder,”Clin. Pharmacol, Ther., 1992, 52(5), 561-568.
Stein, M.A., et al., “Methylphenidate dosing: Twice daily versus three times daily,”Pediactrics., 1996, 98(4), 748-756.
Swanson, J. M., et al., “Analog classroom assessment of Adderall in children with ADHD,”J. Am. Acad Child Adolesc. Psychiatry., 1998, 37(5), 519-525.
Ward, M. F., et al., “The Wender Utah rating scale: an aid in the retrospective diagnosis of chilhood attention deficit hyperactivity disorder,”Am. J. Phychiatry., 1993, 150(6), 885-890.
Zametkin, A. J. and Ernst, M., “Problems in the management of attention-deficit/hyperactivity disorder,”New. Eng. Jour. Med., Jan. 1999, 340(1), 40-46.

Affiliated with

Also associated with

Rating

Process and intermediates for resolving piperidyl acetamide... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process and intermediates for resolving piperidyl acetamide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process and intermediates for resolving piperidyl acetamide... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3458948